Clinical trial
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT00614523 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Lead sponsor
- Amgen
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 21, 2008
- Completion date
- November 30, 2015
- Enrollment
- 250 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.